From current advances to emerging approaches, Marco Ruella, MD (@MarcoRuella), of @PennMedicine shares his perspective on the next chapter of cellular therapy at #CellCoast2026. Key takeaways: ➡️ 10-year CTL019 follow-up data demonstrate durable lymphoma-free survival in a subset of patients with large B-cell and follicular lymphoma. ➡️ CAR T cells can persist for up to a decade in some patients, offering new insights into the cellular characteristics associated with long-term responses. ➡️ Long-term follow-up also highlights important safety considerations, including infections and secondary malignancies, underscoring the need to balance durable efficacy with ongoing safety monitoring.

Live from #CellCoast2026: Stephanie Goff, MD (@slgoff_SB), of @theNCI joins Kedar Kirtane, MD (@DrKedarKirtane) to explore the next generation of personalized tumor-infiltrating lymphocyte therapy.

Live from #CellCoast2026: Jakub Svoboda, MD, joins Marco Ruella, MD (@MarcoRuella), of @PennMedicine to share insights on Penn’s work with IL-18 CAR T-cell therapy.

LIVE from #CellCoast26: Ben Creelan, MD (@BenCreelan), explores the evolving landscape of T-cell engagers (TCEs) versus CAR T-cell and TCR therapies, highlighting their distinct approaches and expanding potential across cancer types, including lung, gastrointestinal and prostate cancers. Key Takeaways: ➡️ T-cell engagers offer an off-the-shelf approach but often require continuous treatment, with challenges including frequent dosing, immunosuppression and treatment costs. ➡️ CAR T-cell therapies aim to deliver durable remissions through a one-time treatment, leveraging the potential for long-term T-cell memory. ➡️ Emerging TCEs, including DLL3-targeting therapies such as tarlatamab in small cell lung cancer and STEAP1-targeting xaluritamig in prostate cancer, highlight the expanding applications of T-cell–directed immunotherapy across solid tumors.

Understanding T-cell engagers—and where they’re headed. Ken Shain, MD, PhD, of @MoffittNews breaks down this approach and discusses emerging directions in cancer treatment at #CellCoast2026. Key takeaways: ➡️ Bispecific antibodies targeting BCMA are reshaping treatment expectations in relapsed/refractory multiple myeloma, with impressive progression-free survival and MRD negativity rates raising questions about their potential role in newly diagnosed disease. ➡️ Combination therapies are showing encouraging activity in high-risk patients. The talquetamab + teclistamab combination demonstrated a 78.9% overall response rate in patients with extramedullary disease in the phase 2 RedirecTT-1 study. ➡️ Despite remarkable efficacy, optimizing treatment safety remains essential. Infection prevention, CRS/ICANS management and understanding resistance mechanisms will be critical to improving outcomes and guiding future treatment strategies.

At #ASTRO26, Issam El Naqa, PhD (@ielnaqa), highlights emerging advances in machine learning and their role in personalized medicine, along with next-generation linear accelerators designed to improve treatment delivery. #MoffittASTRO26

That’s a wrap on #ASTRO26! 👏 Over the past few days, Moffitt experts shared research, presented new findings, connected with colleagues and contributed to important conversations across the field. We’re excited for the future of radiation oncology and already looking forward to #ASTRO27 in Chicago! #MoffittASTRO26